Name: Tim Haines
Organisation: Abingworth
Position: Managing partner
With more than 25 years of international management experience in the life sciences industry in both public and private companies, Tim Haines, managing partner of international investment group Abingworth, takes a spot in LSIPR 50.
Haines joined Abingworth in 2005, an investment company which has raised $375 million since 2010. The company was founded in 1973 and is dedicated exclusively to the life sciences and healthcare sectors.
One of the company’s more notable investments was in CRISPR Therapeutics, an early-stage biopharmaceutical company created to translate CRISPR-Cas9, the breakthrough gene-editing technology, into medicines. The company formed a collaboration with Vertex Pharmaceuticals, in a deal worth up to $2.6 billion